Dimensional Fund Advisors LP Raises Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)

Dimensional Fund Advisors LP raised its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 11.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,702,302 shares of the company's stock after purchasing an additional 178,351 shares during the period. Dimensional Fund Advisors LP owned about 1.86% of Arcus Biosciences worth $25,348,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of RCUS. R Squared Ltd purchased a new stake in Arcus Biosciences in the 4th quarter worth about $26,000. US Bancorp DE grew its holdings in Arcus Biosciences by 2,432.0% in the 4th quarter. US Bancorp DE now owns 6,887 shares of the company's stock valued at $103,000 after buying an additional 6,615 shares during the last quarter. PEAK6 LLC acquired a new position in Arcus Biosciences during the 4th quarter valued at $149,000. AXQ Capital LP bought a new stake in shares of Arcus Biosciences in the fourth quarter valued at about $160,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Arcus Biosciences during the fourth quarter valued at approximately $207,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Arcus Biosciences Trading Up 3.4%

RCUS stock traded up $0.28 during midday trading on Monday, hitting $8.56. The company had a trading volume of 101,131 shares, compared to its average volume of 825,783. The stock has a market cap of $906.59 million, a price-to-earnings ratio of -2.76 and a beta of 0.88. The stock's 50 day moving average price is $8.40 and its 200 day moving average price is $12.35. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. Arcus Biosciences, Inc. has a 52 week low of $6.50 and a 52 week high of $18.98.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.12). Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The company had revenue of $28.00 million for the quarter, compared to analysts' expectations of $38.61 million. During the same quarter in the previous year, the firm posted ($0.05) EPS. The firm's quarterly revenue was down 80.7% compared to the same quarter last year. As a group, equities research analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Arcus Biosciences news, CEO Terry J. Rosen bought 19,800 shares of the company's stock in a transaction on Thursday, February 27th. The shares were bought at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the acquisition, the chief executive officer now directly owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. The trade was a 0.78% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Yasunori Kaneko purchased 20,000 shares of the business's stock in a transaction dated Thursday, February 27th. The stock was bought at an average price of $10.06 per share, for a total transaction of $201,200.00. Following the completion of the acquisition, the director now directly owns 28,400 shares in the company, valued at approximately $285,704. This trade represents a 238.10% increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Wells Fargo & Company cut their price target on shares of Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Barclays cut their price objective on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a research report on Wednesday, April 23rd. The Goldman Sachs Group lowered their target price on Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating for the company in a research note on Thursday. Morgan Stanley lowered their price target on shares of Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a report on Friday. Finally, HC Wainwright upgraded Arcus Biosciences from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $18.00 to $24.00 in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $25.67.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.